BioCentury | Jan 13, 2021
Finance

IPO filing reveals details of Sana’s deep pipeline, aggregation of next-generation gene and cell therapy technologies

...either CD4+ or CD8+ T cells to deliver genetic payloads encoding CARs against CD19 or BCMA...
...cell technology licensed from Harvard University, Sana’s two donor-derived pipeline programs will target CD19 and BCMA.The...
...Fund, The Public Sector Pension Investment Board, GV and the Abu Dhabi Investment Authority.TARGETSBCMA (TNFRSF17; CD269...
BioCentury | Jan 12, 2021
Deals

bluebird’s split could yield two attractive M&A targets

...delay was followed by a May refusal-to-file letter from FDA requesting additional CMC documentation for its BCMA-targeting...
...Johnson & Johnson (NYSE:JNJ). Those partners initiated a rolling BLA submission in December for their BCMA...
...for either side,” he said. bluebird closed up $1.86 to $50.40 on Monday.TARGETSBCMA (TNFRSF17; CD269) - Tumor necrosis factor receptor superfamily member 17 Virginia...
BioCentury | Jan 9, 2021
Finance

4Q20 Wrap: Stocking up

...myeloma, suggested the allogeneic CAR T may be at an efficacy disadvantage compared with autologous BCMA-targeting...
...Johnson (NYSE:JNJ) reported at ASH a 97% ORR for ciltacabtagene autoleucel, its autologous CAR T against BCMA...
...endpoints of a Phase III trial.  TARGETSIRAK4 – Interleukin-1 receptor-associated kinase 4 BCMA (TNFRSF17; CD269) – Tumor necrosis factor receptor superfamily member 17 Meredith...
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...inflection points for individual targets such as BCMA...
...event in CAR Ts will be the BCMA...
...MDD) and post-partum depression (PPD). TARGETSBCMA (TNFRSF17; CD269...
BioCentury | Jan 1, 2021
Regulation

Another year of firsts in FDA’s new drug approvals

...Blenrep belantamab mafodotin-blmf, an antibody-drug conjugate against BCMA...
...flood of new gene therapy approvals.TARGETSBCMA (TNFRSF17; CD269...
BioCentury | Jan 1, 2021
Deals

The good, the bad and the COVID: BioCentury’s playlist for pandemic times

...turning point for several new modalities. Potential BCMA...
BioCentury | Dec 30, 2020
Product Development

2020’s silver linings, New Year’s hopes: a BioCentury podcast

...but we're looking forward to the first BCMA...
BioCentury | Dec 15, 2020
Deals

Hillhouse’s Overland builds momentum with second marquee China deal with Allogene

...exclusive rights to specified Allogene candidates targeting BCMA...
BioCentury | Dec 15, 2020
Product Development

Vaccines march forward & CAR Ts move earlier: a BioCentury podcast

...Ts head to head against STEM cell transplant. We're also seeing I think there's one BCMA...
BioCentury | Dec 11, 2020
Product Development

CAR Ts make the move to earlier lines of treatment despite access barriers

...company is testing idecabtagene vicleucel (ide-cel), a BCMA-targeting...
...alive at four years,” said El-Houssieny.TARGETSBCMA (TNFRSF1; CD269...
Items per page:
1 - 10 of 233